Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Schieffer, B.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Schieffer, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Interaction of interleukin-6 and angiotensin II in atherosclerosis: culprit for inflammation?

B. Schieffer*

Abteilung Kardiologie und Angiologie, Medizinische Hochschule Hannover, Hannover, Germany

* Bernhard Schieffer, MD, Abteilung Kardiologie und Angiologie, Medizinische Hochschule Hannover, Carl Neuberg Strasse 1, 30625 Hannover, Germany
schiefferbernhard{at}mh.hannover

Abstract

Atherosclerosis is a chronic inflammatory disease perpetuated by a variety of pro-inflammatory mediators. Fatal outcomes of this disease, which include myocardial infarction, stroke, and sudden death, remain the major cause of morbidity and mortality in industrialized countries. Accumulated evidence obtained from pathological observations, state-of-the-art imaging, and large-scale clinical trials showed that these fatal events are mainly the results of pathological vascular remodeling processes, suggesting a close interaction between inflammation, vascular remodeling, and the renin-angiotensin system. The Heart Outcomes and Prevention Evaluation (HOPE) study demonstrated that the renin-angiotensin system blockade reduces fatal and nonfatal clinical ischaemic events in high-risk patients, which further implicate the renin-angiotensin system in plaque development and stability. Since experimental and clinical evidence point to inflammatory mediators such as interferon-{gamma}, interleukin-1ß, interleukin-18, and interleukin-10 as well as interleukin-6 as promoters/predictors of cardiovascular events, this paper discusses the clinical basis and the potential molecular and cellular interactions between the RAS and cytokines and their potential impact on remodeling processes at the atherosclerotic plaques.

Key Words: angiotensin II • interleukin-6 • matrix metalloproteinases • C-reactive protein • atherosclerosis • renin-angiotensin system (RAS)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.